Biocytogen published a new Nature Biotechnology study reporting AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations with every submission experimentally evaluated for affinity and developability.
Published
Signal category
Research & Knowledge
Quote
“A new Nature Biotechnology study reports AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations, with every submission experimentally evaluated for affinity and developability.”
— Fengqian Chen, Ph.D.|Biocytogen team
Company
Biocytogen
Your Partner From Targets To Therapeutics
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 229 employees
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
Founded 2009